Skip to main content

Table 2 Administration of levosimendan or placebo

From: Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery: a prospective randomized controlled trial

VariableLevosimendan group (n = 94)Placebo group (n = 93)p value
Time of infusion started after surgery (h)2.27 ± 0.812.39 ± 0.810.453
Interruption of infusion due to adverse events, n (%)6 (6.4%)5 (5.4%)0.770
Duration of infusion, n (%)
 < 243 (3.2%)2 (2.2%)0.659
 24–488 (8.5%)5 (5.4%)0.399
 4883 (88.3%)86 (92.5%)0.333
  1. Data are means ± standard deviation (SD) for continuous variables and number of subjects (n) and percentage (%)for categorical variables